Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.1.6.12 (chondroitinase)
 2,183 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Phospholipase D preferentially contained in human eosinophil polymorphonuclear leukocytes as compared to other leukocytes was isolated by sequential asion and cation exchange chromatography and gel filtration. The purified eosinophil enzyme specifically liberated choline from I-alpha-phosphatidyl choline with a pH optimum of 4.5-6.0 and exhibited a pI of 5.8-6.2 on polyacrylamide-gel isoelectric focusing, which are properties shared by phospholipase D from plant sources; however, its apparent mol wt of 60,000 is approximately one-half that of the plant enzymes. Eosinophil and cabbage phospholipase D inactivated a partially purified rat platelet-activating factor (PAF) in a time- and dose-dependent reaction. The cleavage of this PAF activity was attributed to the inherent phospholipase D activity of the eosinophil enzyme since the two activities chromatographed together at each purification step, and there was apparent reciprocal inhibition of choline-generating activity by PAF and of PAF-inactivating activity by phosphatidyl choline. Thus, possible regulatory functions of the eosinophil in immediate hypersensitivity reactions include inactivation of a PAF by phospholipase D as well as degradation of slow-reacting substance of anaphylaxis by arylsulfatase B.
 ...
PMID:Isolation of human eosinophil phospholipase D. 0 68

Eosinophil migration toward a concentration gradient of a chemotactic factor is regulated at four levels. Diverse immunologic pathways generate stimuli with eosinophil chemotactic activity, including the complement products C5a and a fragment of C3a and the peptide products of mast cells and basophils activated by IgE-mediated reactions, such as eosinophil chemotactic factor of anaphylaxis (ECF-A) and other oligopeptides. The intrinsic preferential leukocyte activity of the chemotactic stimuli represents the second level of modulation, with ECF-A and other mast cell-derived peptides exhibiting the most selective action on eosinophils. The third level of control of eosinophil chemotaxis is composed of inactivators and inhibitors of chemotactic stimuli and is exemplified by degradation of C5a by anaphylatoxin inactivator or chemotactic factor inactivator and of ECF-A by carboxypeptidase-A or aminopeptidases. The activity of ECF-A is uniquely suppressed by equimolar quantities of its NH2- terminal tripeptide substituent, presumably by eosinophil membrane receptor competition. Factors comprising the fourth level of regulation, which alter eosinophil responsiveness to chemotactic stimuli, include the chemotactic factors themselves, through deactivation; nonchemotactic inhibitors such as the COOH-terminal tripeptide substituent of ECF-A, the neutrophil-immobilizing factor (NIF), the phagocytosis-enhancing factor Thr-Lys-Pro-Arg, and histamine at concentrations greater than 400 ng/ml; and nonchemotactic enhancing principles represented by ascorbate and by histamine at concentrations of 30 ng/ml or less. Local concentrations of eosinophils called to and immobilized at the site of a hypersenitivity reaction may express their regulatory functions by degrading the chemical mediators elaborated including histamine, slow-reacting substance of anaphylaxis (SRS-A), and platelet-activating factor (PAF) by way of their content of histaminase, arylsulfatase B, and phospholipase D, respectively. Immunologic pathways may thus provide the capability for early and specific host defense reactions with a later influx of eosinophils preventing irreversible local tissue alterations or distant organ effects.
 ...
PMID:Modulation of human eosinophil polymorphonuclear leukocyte migration and function. 79 10

Recently four tissue toxic proteins namely major basic protein (MBP), eosinophil peroxidase (EPO), eosinophil-derived neurotoxin (EDN), and eosinophil cationic protein (ECP) were found in eosinophilic leucocytes. Although the characteristics of these proteins concerning tissue damage in the local site of type I allergic reaction have been investigated mainly in lower respiratory tract, the actual clinico-pathological roles of these proteins in nasal allergy are not clarified. Contrary, eosinophils also have histaminase, arylsulfatase, phospholipase D, which are considered to act on a negative feedback mechanism in allergic reaction through inactivation of chemical mediators. Therefore, estimation of ECP and simultaneously arylsulfatase B in nasal secretion and the sera from patients with nasal allergy may clarify the dynamics of clinico-pathological state, especially in the late phase of allergic reaction in each patients. ECP concentrations in the nasal secretions from 22 patients and in the sera from 12 patients with nasal allergy were measured by RIA method. The activities of arylsulfatase B in the nasal secretions and the sera were also estimated in the same specimens as ECP by measuring its hydrolytic activity using p-nitro cathecol sulfate as a substrate. The results obtained were as follows; 1) There was a significant correlation between ECP concentrations in the nasal secretions and the severities of clinical symptoms, especially the degree of nasal obstruction. ECP concentrations also significantly correlated to the score of eosinophilic leucocytes in the nasal smears. 2) The serum ECP concentrations significantly correlated to the number of eosinophilic leucocytes in the peripheral blood, and also showed slight tendency of correlation to the severity of clinical symptoms.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:[Study on eosinophil cationic protein (ECP) and arylsulfatase B in nasal secretions and sera from patients with nasal allergy]. 188 31

We have shown previously that chondroitin sulfate, but not heparan sulfate/heparin, linked to either natural core proteins or serum albumin interferes with cell-to-substrate adhesion, provided that the external proteoglycans are topologically immobilized on plastic plates. In order to study the roles of glycosaminoglycan chains (GAGs) as recognition structure, a new assay system is now developed which involves the conversion of free GAGs to reactive lactone derivatives selectively modified at the reducing end. The modified GAGs can be coupled to the amino group of phosphatidylethanolamino (PE) for use as probes on either plastic plates or cell surfaces. Incubation of GAG-PE solutions in polystyrene plates results in a time- and dose-dependent increase of the density of the GAG chains noncovalently immobilized onto the plates. No immobilization is detected with any of the GAG-PE samples that have been treated with phospholipase D. A M(r) 30,000 chondroitin sulfate conjugate to PE (CS-PE), when immobilized onto a fibronectin-coated well for 2 h at an initial concentration of 0.06 microgram/100 microliters/well, inhibits the adhesion of baby hamster kidney (BHK) cells to the substratum by approximately 50%, whereas heparin-, heparan sulfate-, hyaluronic acid-, and dermatan sulfate-PE do not. The effect of CS-PE is abolished by treating the CS-PE-coated plates with chondroitinase ABC. A similar level of inhibition by CS-PE is found when the RGD-containing 120-kDa fragment of fibronectin is used in place of fibronectin. CS-PE in soluble form, once exposed to BHK cells in suspension, can be associated with the cell surfaces, thereby exerting some inhibitory effects on cell-to-substrate adhesion. On a per mol basis, however, the activity of cell-associated CS-PE is far lower than that of substrate-associated CS-PE. Together the results indicate that our GAG-PEs offer useful tools for probing regulatory function of the GAG moieties of proteoglycans and further support the hypothesis that the inhibitory regulation of cell-to-matrix adhesion by large chondroitin sulfate proteoglycans is caused by an interaction between the cell surface and the chondroitin sulfate chains topologically immobilized on extracellular matrices.
 ...
PMID:Preparation of lipid-derivatized glycosaminoglycans to probe a regulatory function of the carbohydrate moieties of proteoglycans in cell-matrix interaction. 834 Apr 4